Ursodeoxycholic Acid Market Report 2026

The ursodeoxycholic acid market size has grown rapidly in recent years. It will grow from $0.96 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to limited production methods for ursodeoxycholic acid, reliance on animal-derived extraction, growing awareness of liver disease management, increasing hospital and specialty clinic treatments, limited research on non-alcoholic fatty liver disease.

The ursodeoxycholic acid market size is expected to see rapid growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to advancements in chemical and enzymatic synthesis, rising prevalence of liver and biliary diseases, expansion of specialty clinics and research institutions, increased regulatory approvals for synthetic udca, development of novel administration formulations. Major trends in the forecast period include rising prevalence of gallstones and cholestatic liver disorders, increased adoption of synthetic and biosynthetic udca, expansion of oral and intravenous administration routes, growing use in research and clinical trials for liver diseases, focus on personalized treatment and dosage optimization.

The increasing prevalence of liver diseases is expected to propel the growth of the ursodeoxycholic acid market going forward. Liver diseases include a range of conditions that affect the liver’s ability to function effectively, such as infections, inflammation, fatty liver disease, cirrhosis, and liver cancer. The rising prevalence of liver diseases is largely attributed to increased alcohol consumption, as prolonged excessive drinking can cause significant liver damage. Ursodeoxycholic acid supports the treatment of liver diseases by improving bile flow and reducing toxic bile acids, making it effective in managing conditions such as primary biliary cholangitis. It improves patient outcomes by slowing the progression of liver damage and assisting in the dissolution of cholesterol gallstones, thereby enhancing overall treatment effectiveness. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, there were 6,664 premature deaths from liver disease among males and 3,929 among females, representing a 22.8% increase for males and a 33.1% increase for females compared to 2023. Therefore, the rising prevalence of liver diseases is driving the growth of the ursodeoxycholic acid market.

The growing aging population is expected to propel the growth of the ursodeoxycholic acid market in the coming years. The aging population refers to the increasing proportion of elderly individuals within the overall population. This demographic shift has significant implications for economies, healthcare systems, and social support structures worldwide. Older individuals are more susceptible to various health conditions, including liver-related disorders, increasing the need for early diagnosis, preventive care, and effective treatment options. Ursodeoxycholic acid is widely used among aging populations to support liver function by treating cholestatic liver diseases and enhancing bile flow. For instance, in January 2024, according to data published by the Pew Research Center, a US-based organization, the aging population stood at 101,000 in 2024 and is projected to increase to 420,000 by 2054. Therefore, the rising aging population is driving the growth of the ursodeoxycholic acid market.

Major companies operating in the ursodeoxycholic acid (UDCA) market are focusing on developing innovative therapies, such as bile acid derivatives, to improve the treatment of liver diseases, particularly cholestatic liver disorders. Bile acid derivatives are modified forms of bile acids designed to enhance therapeutic efficacy and support liver function. For instance, in November 2024, Nora Pharma Inc., a Canada-based pharmaceutical company, launched a generic version of Ursodiol (ursodeoxycholic acid) for the treatment of cholestatic liver diseases, including primary biliary cholangitis (PBC). This medication is primarily used to improve liver function and slow disease progression, especially when initiated at an early stage. It also helps dissolve and prevent cholesterol gallstones by altering bile composition and reducing harmful bile acids.

Major companies operating in the ursodeoxycholic acid market are Mankind Pharma Pvt. Ltd, Abbott Healthcare Pvt. Ltd., Shandong Octagon Chemicals Limited, J.S.C. Grindeks, Arch Pharmalabs, Ind Swift Laboratories Ltd., Symbiotec Pharmalab, Suzhou Tianlu Bio-pharmaceutical Co. Ltd, Zeal MediPharma, Prodotti Chimici e Alimentari S.P.A., Mitsubishi Tanabe Pharma Corporation, ICE Pharma Inc, Xi'an Tian Guangyuan Biotech Co. Ltd, Aamorb Pharmaceuticals Inc., Axplora Inc, Octavius Pharma Pvt. Ltd, Sichuan Elixir Pharmaceutical Co. Ltd, Signova Pharma Pvt. Ltd., Sinoway Industrial Co. Ltd, Valence Labs Pvt. Ltd.

North America was the largest region in the ursodeoxycholic acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ursodeoxycholic acid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ursodeoxycholic acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the ursodeoxycholic acid market by increasing the cost of imported raw materials and synthesis equipment, particularly impacting synthetic and enzymatically synthesized UDCA segments. Regions in Asia-Pacific such as China and India, which are major production hubs, face higher import duties, leading to increased production costs and potential supply delays. Positive impacts include encouragement of local manufacturing, development of alternative synthesis methods, and investment in domestic research and production capacities.

The ursodeoxycholic acid market research report is one of a series of new reports that provides ursodeoxycholic acid market statistics, including ursodeoxycholic acid industry global market size, regional shares, competitors with a ursodeoxycholic acid market share, detailed ursodeoxycholic acid market segments, market trends and opportunities, and any further data you may need to thrive in the ursodeoxycholic acid industry. This ursodeoxycholic acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ursodeoxycholic acid (UDCA) is a bile acid that is naturally produced in small quantities by the human liver and is used therapeutically to dissolve certain types of gallstones and to treat specific liver and gallbladder disorders. It works by dissolving cholesterol gallstones, improving bile flow, and protecting liver cells from injury. Ursodeoxycholic acid is widely regarded as a safe and effective treatment option for managing cholestatic liver diseases.

The main types of ursodeoxycholic acid include synthetic ursodeoxycholic acid and extraction-derived ursodeoxycholic acid. Synthetic ursodeoxycholic acid is a laboratory-produced form of the natural bile acid used to manage liver conditions and dissolve cholesterol gallstones by enhancing bile circulation and reducing liver cell damage. It can be administered through oral, intravenous, or subcutaneous routes and is mainly used in the treatment of gallstones, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, and other hepatic and biliary disorders. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, specialty clinics, research institutions, and other healthcare providers.

The ursodeoxycholic acid market consists of sales of ursodiol tablets, ursodeoxycholic acid capsules, suspensions, injectables, and combination drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.